Current Knowledge and Future Direction of Research on Soy Isoflavones as a Therapeutic Agents

Pharmacognosy Review,2010,4,8,111-117.
Published:October 2010
Type:Review Article
Author(s) affiliations:

V. Kalaiselvan, M. Kalaivani1, A. Vijayakumar1, K. Sureshkumar1, K. Venkateskumar1

1Indian Pharmacopoeia Commission, Sector 23, Raj Nagar, Ghaziabad- 201002, Uttar Pradesh, INDIA.

2KMCH College of Pharmacy, Kovai Estate, Kalapatti road, Coimbatore-42, Tamil Nadu, INDIA.


Isoflavones, the most abundant phytoestrogens in Soy beans, are structurally similar to 17beta-estradiol. The antioxidant property of the soy isoflavones, namely, genistein and daidzein is well established in different experimental models and also in clinical studies. The compounds have been found effective in the management of diabetes by acting on peroxisome proliferator-activated receptors. It reduces the risk of coronary heart disease by reducing the level of low-density lipoprotein and triglycerides. Soy isoflavones have the potential in the treatment of osteoporosis to act on osteoclasts further to inhibit tyrosine kinase. Among the soy isoflavones, genistein is the potential compound found effective in the treatment of cancer by acting on androgen receptor further to inhibit tyrosine kinases. In this article, various aspects of the diverse biological activities of soy isoflavones and their potential clinical implications with mechanism of action, especially in the treatment and prevention of diabetes, cardiovascular diseases, cancer, osteoporosis, neuroprotection, and also future area of research on soy isoflavones are reviewed and discussed.

Cite This Article

Vancouver Style ::
V. Kalaiselvan, Kalaivani, M. , Vijayakumar, A. , Sureshkumar, K. , and Venkateskumar, K. , Current Knowledge and Future Direction of Research on Soy Isoflavones as a Therapeutic Agents, Pharmacognosy Review, vol. 4, no. 8, pp. 111-117, 2010.